natgillin/translations-raw huggingface dataset:
Skin exfoliation, photosensitivity reaction, pigmentation abnormal
luščenje kože, preobčutljivostne reakcije na svetlobo, nenormalna pigmentacija eritem, nenormalna pigmentacija, povečano znojenje
- the same Grade 3 non-haematological toxicity (except for alopecia, nausea, vomiting) recurs after dose reduction.
- po zmanjšanju odmerka ponovno nastopi ista nehematološka toksičnost 3. stopnje (z izjemo alopecije, slabosti in bruhanja).
Temozolomide SUN 5 mg hard capsules
Temozolomid SUN 5 mg trde kapsule
Very rare cases of lung side effects have been observed with Temozolomide SUN.
Pri zdravljenju z zdravilom Temozolomid SUN so opazili zelo redke primere neželenih učinkov na pljuča.
The body is imprinted with ‘100 mg' and two stripes.
Na telesu so odtisnjene oznaka »100 mg« in dve črti.
Neutropenia, thrombocytopenia, lymphopenia, leukopenia
trombocitopenija, anemija, levkopenija
Patients with newly-diagnosed glioblastoma multiforme
Bolniki z na novo diagnosticiranim multiformnim glioblastomom
Haemorrhage, deep venous thrombosis, oedema leg
krvavitve, edem, edem nog krvavitve, globoka venska tromboza, edem nog
SUN Pharma logo
IME IMETNIKA DOVOLJENJA ZA PROMET Z ZDRAVILOM SUN Pharma logo
Temozolomide SUN 140 mg hard capsules
Temozolomid SUN 140 mg trde kapsule
Temozolomide SUN 180 mg hard capsules
Temozolomid SUN 180 mg trde kapsule
Temozolomide SUN 20 mg hard capsules temozolomide
Temozolomid SUN 20 mg trde kapsule temozolomid
Temozolomide SUN 5 mg hard capsules temozolomide
Temozolomid SUN 5 mg trde kapsule temozolomid
Temozolomide SUN 140 mg hard capsules have a white opaque body and cap, imprinted in blue ink.
Temozolomid 140 mg trde želatinske kapsule imajo bel neprosojen pokrovček in telo z modrim potiskom.
Temozolomide SUN 5 mg hard capsules have a white opaque body and cap, imprinted in green ink.
Temozolomid 5 mg trde želatinske kapsule imajo bel neprosojen pokrovček in telo z zelenim potiskom.
Κύπρος/Latvija/Lietuva/Luxembourg/Luxemburg/Magyarország/
België/Belgique/Belgien/България/Česká republika/ Danmark/Eesti/Ελλάδα/Hrvatska/Ireland/Ísland/ Κύπρος/Latvija/Lietuva/Luxembourg/Luxemburg/Magyarország/
Temozolomide SUN 140 mg hard capsules temozolomide
Temozolomid SUN 140 mg trde kapsule temozolomid
Prior to dosing, the following laboratory parameters must be met: ANC ≥ 1.5 x 109/l and platelet count ≥ 100 x 109/l.
dokler ni ANC > 1,5 x 109/l in število trombocitov > 100 x 109/l.
- absolute neutrophil count (ANC) ≥ 1.5 x 109/l
ANC ≥ 1,5 x 109/l in število trombocitov ≥ 100 x 109/l.
Temozolomide SUN contains a medicine called temozolomide.
Kaj vsebuje zdravilo Temozolomid SUN - Zdravilna učinkovina je temozolomid.
Temozolomide SUN 100 mg hard capsules
Temozolomid SUN 100 mg trde kapsule
Temozolomide SUN 250 mg hard capsules temozolomide
Temozolomid SUN 250 mg trde kapsule temozolomid
Temozolomide SUN 180 mg hard capsules have a white opaque body and cap, imprinted in red ink.
Temozolomid 180 mg trde želatinske kapsule imajo bel neprosojen pokrovček in telo z rdečim potiskom.
EXP
eksantem
See footnote b
PRILOGA I
Temozolomide SUN 180 mg hard capsules temozolomide
Temozolomid SUN 180 mg trde kapsule temozolomid
TMZ administration can be continued throughout the 42 day concomitant period (up to 49 days) if all of the following conditions are met:
skupaj 42 dni (do največ 49 dni).
Temozolomide SUN 100 mg hard capsules temozolomide
Temozolomid SUN 100 mg trde kapsule temozolomid
Anxiety, depression, emotional lability, insomnia
zaskrbljenost, čustvena nestabilnost, nespečnost zaskrbljenost, depresija, čustvena nestabilnost, nespečnost
Urinary incontinence
inkontinenca seča inkontinenca seča
Propylene glycol Red iron oxide (E172)
Rdeči železov oksid (E172)
Embolism pulmonary, oedema, oedema peripheral
možganske krvavitve, hipertenzija pljučna embolija, edem, periferni edem
Hard gelatin capsules, with white opaque cap and body, imprinted in black ink.
Trde želatinske kapsule imajo bel neprosojen pokrovček in telo s črnim potiskom.
Hemiparesis, aphasia, balance impaired, somnolence, confusion, dizziness, memory impairment, concentration impaired, dysphasia, neurological disorder (NOS), neuropathy, peripheral neuropathy, paresthesia, speech disorder, tremor
zmedenost, omotica, motnje spomina, zmanjšanje miselne zbranosti, disfazija, nevrološke motnje (NOS), nevropatija,
Hard gelatin capsules, with white opaque cap and body, imprinted in blue ink.
Trde želatinske kapsule imajo bel neprosojen pokrovček in telo z modrim potiskom.
Fever, asthenia, rigors, malaise, pain, taste perversion
zvišana telesna temperatura, astenija, mrzlica, slabo počutje, bolečine, motnje okusa
Allergic reaction, fever, radiation injury, face oedema, pain, taste perversion
alergijska reakcija, zvišana telesna temperatura, radiacijske poškodbe, edem obraza, bolečine, motnje okusa alergijska reakcija, zvišana telesna temperatura, radiacijske poškodbe, bolečine
Temozolomide SUN 140 mg
PODATKI V BRAILLOVI PISAVI Temozolomid SUN 140 mg
Temozolomide SUN is used for the treatment of specific forms of brain tumours: - in adults with newly-diagnosed glioblastoma multiforme.
Zdravilo Temozolomid SUN se uporablja za zdravljenje določenih vrst možganskih tumorjev:
Your doctor will work out your dose of Temozolomide SUN.
Odmerek zdravila Temozolomid SUN bo določil zdravnik.
Package Leaflet: Information for the user Temozolomide SUN 250 mg hard capsules temozolomide
Navodilo za uporabo Temozolomid SUN 250 mg trde kapsule temozolomid
- The other ingredients are: capsule content: lactose, sodium starch glycolate (Type B), tartaric acid, stearic acid (see section 2 "Temozolomide SUN contains lactose") capsule shell: gelatin, titanium dioxide (E171), sodium laurilsulfate printing ink: shellac, propylene glycol, titanium dioxide (E171), blue #1/Brilliant Blue FCF Aluminium Lake (E133).
ovoj kapsule: želatina, titanov dioksid (E171), natrijev lavrilsulfat črnilo: šelak, propilenglikol, titanov dioksid (E171), modro aluminijevo barvilo FCF št.1 (E133)
Infections and infestations Common:
Očesne bolezni Pogosti:
Temozolomide SUN 100 mg hard capsules have a white opaque body and cap, imprinted in pink ink.
Temozolomid 100 mg trde želatinske kapsule imajo bel neprosojen pokrovček in telo z rožnatim potiskom.
Propylene glycol Black iron oxide (E172)
Črni železov oksid (E172)
Hard gelatin capsules, with white opaque cap and body, imprinted in red ink.
Trde želatinske kapsule imajo bel neprosojen pokrovček in telo z rdečim potiskom.
Stomatitis, diarrhoea,
nevtropenija, trombocitopenija,
- if you have had an allergic reaction to dacarbazine (an anticancer medicine sometimes called DTIC).
Ne jemljite zdravila Temozolomid SUN - če ste alergični na temozolomid ali katerokoli sestavino tega zdravila (navedeno v poglavju 6); - če ste kdaj imeli alergijsko reakcijo na dakarbazin (zdravilo proti raku, ki ga včasih imenujemoDTIC); med znaki alergijske reakcije vključujejo srbenje, zasoplost ali hropenje,
Hemiparesis, aphasia, balance impaired, somnolence, confusion, dizziness, memory impairment, concentration impaired, dysphasia,
somnolenca, afazija, motnje ravnotežja, omotica,
EU/1/11/697/017 (5 hard capsules) EU/1/11/697/018 (20 hard capsules)
EU/1/11/697/017 (5 kapsul v pretisnem omotu) EU/1/11/697/018 (20 kapsul v pretisnem omotu)
- The other ingredients are: capsule content: lactose, sodium starch glycolate (Type B), tartaric acid, stearic acid (see section 2 "Temozolomide SUN contains lactose") capsule shell: gelatin, titanium dioxide (E171), sodium laurilsulfate printing ink: shellac, propylene glycol, yellow iron oxide (E172), blue #1/Brilliant Blue FCF Aluminium Lake (E133).
ovoj kapsule: želatina, titanov dioksid (E171), natrijev lavrilsulfat črnilo: šelak, propilenglikol, rumeni železov oksid (E172), Modro aluminijevo barvilo FCF št.1 (E133)
- The other ingredients are: capsule content: lactose, sodium starch glycolate (Type B), tartaric acid, stearic acid (see section 2 "Temozolomide SUN contains lactose") capsule shell: gelatin, titanium dioxide (E171), sodium laurilsulfate printing ink: shellac, propylene glycol, red iron oxide (E172), yellow iron oxide (E172), titanium dioxide (E171).
ovoj kapsule: želatina, titanov dioksid (E171), natrijev lavrilsulfat črnilo: šelak, propilenglikol, rdeči železov oksid (E172), rumeni železov oksid (E172), titanov dioksid (E171)
An overdose of 10,000 mg (total dose in a single cycle, over 5 days) was taken by one patient and the adverse reactions reported were pancytopenia, pyrexia, multiorgan failure and death.
Med prijavljenimi neželenimi učinki so bili pancitopenija, pireksija, odpoved več organov in smrt.
Temozolomide SUN 180 mg
PODATKI V BRAILLOVI PISAVI Temozolomid SUN 180 mg
Hard gelatin capsules, with white opaque cap and body, imprinted in green ink.
Trde želatinske kapsule imajo bel neprosojen pokrovček in telo z zelenim potiskom.
Deutschland tel. +49 214 403 990
Italia tel. +39 02 33 49 07 93
Talk to your doctor, pharmacist or nurse before taking Temozolomide SUN,
Pred začetkom jemanja zdravila Temozolomid SUN se posvetujte z zdravnikom, farmacevtom ali medicinsko sestro:
Nederland/Pays-Bas/Niederlande/Нидерландия/Nizozemsko/ Nederlandene/Holland/Ολλανδία/Nizozemska/The Netherlands/Holland/ Ολλανδία/Nīderlande/Nyderlandai/Pays-Bas/Niederlande/Hollandia/ L-Olanda/Nederland/Nederland/Niederlande/Países Baixos/ Nizozemska/Holandsko/Alankomaat/Nederländerna/Nederländerna Tel./тел./tlf./τηλ./Sími/τηλ./Tlf./Puh./
Nederlandene/Holland/Ολλανδία/Nizozemska/The Netherlands/Holland/ Ολλανδία/Nīderlande/Nyderlandai/Pays-Bas/Niederlande/Hollandia/
EU/1/11/697/015 (5 hard capsules) EU/1/11/697/016 (20 hard capsules)
EU/1/11/697/015(5 kapsul v pretisnem omotu) EU/1/11/697/016 (20 kapsul v pretisnem omotu)
Status epilepticus, extrapyramidal disorder, hemiparesis, ataxia, cognition impaired, dysphasia, gait abnormal, hyperesthesia, hypoesthesia, neurological disorder (NOS), peripheral neuropathy
hemipareza, ataksija, motnje kognitivnih procesov, disfazija,nenormalna hoja, hiperestezija, hipoestezija,
Pneumocystis jiroveciipneumonia
periferna nevropatija
EU/1/11/697/023 (5 hard capsules) EU/1/11/697/024 (20 hard capsules)
EU/1/11/697/023 (5 kapsul v pretisnem omotu) EU/1/11/697/024 (20 kapsul v pretisnem omotu)
EU/1/11/697/019 (5 hard capsules) EU/1/11/697/020 (20 hard capsules)
EU/1/11/697/019 (5 kapsul v pretisnem omotu) EU/1/11/697/020 (20 kapsul v pretisnem omotu)
EU/1/11/697/021 (5 hard capsules) EU/1/11/697/022 (20 hard capsules)
EU/1/11/697/021 (5 kapsul v pretisnem omotu) EU/1/11/697/022 (20 kapsul v pretisnem omotu)
EXPIRY DATE
periferni edem
Slovenija/Slovenská republika/Suomi/Finland/Sverige
Malta/Nederland/Norge/Österreich/Portugal/ Slovenija/Slovenská republika/Suomi/Finland/Sverige Sun Pharmaceutical Industries Europe B.V.
EU/1/11/697/013 (5 hard capsules) EU/1/11/697/014 (20 hard capsules)
EU/1/11/697/013 (5 kapsul v pretisnem omotu) EU/1/11/697/014 (20 kapsul v pretisnem omotu)
Then you will have 23 days without Temozolomide SUN.
Nato 23 dni ne boste jemali zdravila Temozolomid SUN. Skupaj je to 28-dnevni cikel zdravljenja.
Hard gelatin capsule, with white opaque cap and body, imprinted in yellow ink.
Trde želatinske kapsule imajo bel neprosojen pokrovček in telo z rumenim potiskom.
Hard gelatin capsules, with white opaque cap and body, imprinted in pink ink.
Trde želatinske kapsule imajo bel neprosojen pokrovček in telo z rožnatim potiskom.
Temozolomide SUN 100 mg
PODATKI V BRAILLOVI PISAVI Temozolomid SUN 100 mg
You should stop breast-feeding while receiving treatment with Temozolomide SUN.
V nekaterih primerih je treba zdravljenje z zdravilom Temozolomid SUN končati.
MA (EU) number (Invented) name Strength Pharmaceutical Form
Läkemedelsform Administreringssätt Innerförpackning Förpackningsstorlek
Pack size
Styrka
Route of Administration
Läkemedlets namn
ATCvet code: QI06AJ05.
Oznaka ATCvet: QI06AJ05.
Store and transport refrigerated (2 °C - 8 °C).
Shranjujte in prevažajte v hladilniku (2°C - 8°C).
Under field conditions, only sub-group A is infective and immunisation against sub-group A provides full protection against A, B and C. After inoculation, the virus expresses the protective proteins, but does not replicate in the cat.
V naravi je infektivna le podskupina A. Imunizacija proti podskupini A pa omogoča popolno zaščito proti A, B in C. Po inokulaciji virus izraža zaščitne proteine, ne da bi se v mački pomnoževal.
Safety and efficacy data are available which demonstrate that this vaccine can be administered the same day but not mixed with Merial adjuvanted vaccine against rabies.
Podatki o varnosti in učinkovitosti so pokazali, da je to cepivo varno dati isti dan, vendar ne zmešano z
* less than 1 animal in 10,000 animals displaying adverse reaction(s) during the course of one treatment, including isolated reports.
*manj kot 1 žival od 10.000 živali kaže neželene učinke med trajanjem enega zdravljenja, vključujoč posamezne primere.
EU/2/04/047/001 lyophilisate (10 bottles of 1 dose) + solvent (10 bottles of 1 ml) EU/2/04/047/002 lyophilisate (50 bottles of 1 dose) + solvent (50 bottles of 1 ml)
EU/2/04/047/001 Liofilizat (10 stekleničk z 1 odmerkom) in vehikel (10 stekleničk po 1 ml) EU/2/04/047/002 Liofilizat (50 stekleničk z 1 odmerkom) in vehikel (50 stekleničk po 1 ml)
Do not mix with any other veterinary medicinal product, except the solvent supplied for use with the product.
Ne mešajte z nobenim drugim zdravilom razen s topilom, ki je priloženo za uporabo s tem cepivom.
Special precautions to be taken by the person administering the veterinary medicinal product to animals: In case of accidental self-injection, seek medical advice immediately and show the package insert or the label to the physician.
Posebni previdnostni ukrepi, ki jih mora izvajati oseba, ki živalim daje zdravilo: V primeru nenamernega samo-injiciranja se takoj posvetujte z zdravnikom in mu pokažite navodila za uporabo ali nalepko na zunanji ovojnini.
Revaccination: - the first revaccination must be carried out for all components one year after the primary vaccination course, - subsequent revaccinations must be carried out: every year for the chlamydiosis and feline leukaemia components and at intervals of up to three years for the rhinotracheitis, calicivirosis and panleucopenia components.
Ponovno cepljenje: - prvo ponovno cepljenje je potrebno opraviti za vse komponente eno leto po osnovnem cepljenju, - nadaljnja ponovna cepljenja je potrebno opraviti: vsako leto za komponenti klamidioza in leukemija mačk in v obdobjih do 3 leta za komponente rinotraheitisa, kaliciviroze in panleukopenije.
A. MANUFACTURERS OF THE BIOLOGICAL ACTIVE SUBSTANCES AND
A. IZDELOVALCI BIOLOŠKIH ZDRAVILNIH UČINKOVIN IN IMETNIK
The frequency of adverse reactions is defined using the following convention: - very common (more than 1 in 10 animals displaying adverse reaction(s) during the course of one treatment) - common (more than 1 but less than 10 animals in 100 animals) - uncommon (more than 1 but less than 10 animals in 1,000 animals ) - rare (more than 1 but less than 10 animals in 10,000 animals) - very rare (less than 1 animal in 10,000 animals, including isolated reports).
- pogosti (pojavijo se pri več kot 1 toda manj kot pri 10 živalih od 100 živali) - občasni (pojavijo se pri več kot 1 toda manj kot pri 10 živalih od 1.000 živali) - redki (pojavijo se pri več kot 1 toda manj kot pri 10 živalih od 10.000 živali)
The product was shown to reduce excretion of feline calicivirus at onset of immunity and for one year after vaccination.
Cepivo dokazano zmanjša izločanje kalicivirusa mačk ob nastopu imunosti in do enega leta po cepljenju.
As a consequence, the vaccine induces an immune status against feline leukaemia virus.
Posledica tega je, da cepivo vzpodbudi imunski odgovor proti virusu mačje levkemije.
The feline leukaemia vaccine strain is a recombinant canarypox virus expressing the env and gag genes of FeLV-A.
Sev virusa v cepivu proti mačji levkemiji je rekombinantni poxvirus kanarčkov, ki izraža env in gag gene FeLV-A.
A. MANUFACTURERS OF THE BIOLOGICAL ACTIVE SUBSTANCES AND MANUFACTURER RESPONSIBLE FOR BATCH RELEASE
A. IZDELOVALCI BIOLOŠKIH ZDRAVILNIH UČINKOVIN IN IMETNIK DOVOLJENJA ZA IZDELAVO ZDRAVILA, ODGOVOREN ZA SPROŠČANJE SERIJE
No effect other than those already mentioned in section 4.6 “Adverse reactions” have been observed, except hyperthermia that may exceptionally last 5 days.
4.10 Preveliko odmerjanje (simptomi, nujni ukrepi, protistrupi), če je potrebno Drugi učinki, razen tistih, ki so navedeni v poglavju 4.6 »Neželeni učinki«, niso znani, razen povišane temperature , ki izjemoma lahko traja pet dni.
Purevax RCPCh FeLV lyophilisate and solvent for suspension for injection
Purevax RCPCh FeLV liofilizat in vehikel za suspenzijo za injiciranje
The duration of immunity after the last re-vaccination is 3 years for the rhinotracheitis, calicivirosis and panleucopenia components, and 1 year for the Chlamydophila felis and feline leukaemia components.
Trajanje imunosti je 3 leta po zadnjem ponovnem cepljenju za komponente kužnega rinotraheitisa, kaliciviroze in panleukopenije, ter 1 leto za komponenti Chlamydophila felis in leukemija mačk.
Disodium phosphate dihydrate Magnesium chloride hexahydrate Calcium chloride dihydrate
Natrijev hidrogenfosfat dihidrat Magnezijev klorid heksahidrat Kalcijev klorid dihidrat
For the full list of excipients, see section 6.1.
2 50% infektivni odmerek za embrionirana kokošja jajca Za celoten seznam pomožnih snovi, glejte poglavje 6.1.
Inject by subcutaneous route one dose (1 ml) of vaccine after reconstitution of the lyophilisate with the solvent, according to the following vaccination scheme:
Po rekonstituciji liofilizirane sestavine z vehiklom injicirajte odmerek (1-ml) cepiva v podkožje, po naslednjem razporedu:
Active immunisation of cats aged 8 weeks and older: - against feline viral rhinotracheitis to reduce clinical signs, - against calicivirus infection to reduce clinical signs, - against Chlamydophila felis infection to reduce clinical signs, - against feline panleucopenia to prevent mortality and clinical signs, - against leukaemia to prevent persistent viraemia and clinical signs of the related disease.
Aktivna imunizacija 8 tednov starih mačk in starejših: - proti kužnemu rinotraheitisu mačk, za ublažitev kliničnih znamenj, - proti okužbam s kalicivirusi, za ublažitev kliničnih znamenj,
In very rare* cases, hyperthermia and lethargy sometimes associated with lameness has been observed one to three weeks following booster vaccination in adult cats.
V zelo redkih primerih* sta se en teden do tri tedne po ponovnem cepljenju pri odraslih mačkah pojavili prehodna hipertermija in letargičnost, včasih tudi v povezavi s šepanjem.
It is recommended that a test for FeLV antigenaemia be carried out prior to vaccination.
Pred cepljenjem je priporočljivo opraviti test na prisotnost antigenov FeLV v krvi.
Stimulates active immunity against feline rhinotracheitis herpesvirus, feline calicivirus, Chlamydophila felis, feline panleucopenia virus and feline leukaemia virus.
Vzpodbuja aktivno imunost proti herpesvirusu kužnega rinotraheitisa, kalicivirusu, Chlamydophila felis, ter virusu panleukopenije in leukemije mačk.
2 egg infective dose 50%
1 50% infektivni odmerek za celično kulturo 2 50% infektivni odmerek za embrionirana kokošja jajca
Attenuated feline rhinotracheitis herpesvirus (FHV F2 strain) ....................................... ≥ 104.9 CCID501 Inactivated feline calicivirus (FCV 431 and G1 strains) antigens ................................... ≥ 2.0 ELISA U. Attenuated Chlamydophila felis (905 strain) ...................................................................... ≥ 103.0 EID502 Attenuated feline panleucopenia virus (PLI IV) ............................................................. ≥ 103.5 CCID501
Inaktivirani antigeni kalici virusa mačk (seva FCV 431 in G1) ....................... ≥ 2,0 enot v testu ELISA Atenuirana Chlamydophila felis (sev 905) ......................................................................... ≥ 103,0 EID502 Atenuiran virus panleukopenije mačk (PLI IV) .............................................................. ≥ 103,5 CCID501
In normal conditions of use, transient apathy and anorexia may occasionally occur, as well as hyperthermia (lasting usually for 1or 2 days).
Pri normalnih pogojih uporabe se lahko občasno pojavijo prehodna apatija in neješčnost.
Manufacturer responsible for the batch release: MERIAL
Izdelovalec, odgovoren za sproščanje serij:
Where high levels of maternal antibodies against rhinotracheitis, calicivirosis, panleucopenia or Chlamydophila components are expected to be present (e.g. in kittens of 9-12 weeks of age born from queens, which were vaccinated before pregnancy and/or with known or suspected previous exposure to the pathogen(s)), the primary vaccination course should be delayed until 12 weeks of age.
ki so bile cepljene pred brejostjo in/ali je znano ali verjetno, da so bile predhodno izpostavljene patogenu (om)), je potrebno osnovno cepljenje odložiti do starosti 12 tednov.
Laboratoire Porte des Alpes Rue de l'Aviation
Laboratoire Porte des Alpes Rue de l'Aviation 69800 Saint Priest FRANCIJA
Special precautions for use in animals:
Posebni previdnostni ukrepi za uporabo pri živalih: Cepite le zdrave živali.
Vaccine against feline viral rhinotracheitis, feline calicivirosis, chlamydiosis, feline panleucopenia and feline leukaemia.
Cepivo proti virusnemu rinotraheitisu, kalicivirusu, klamidiozi, panleukopeniji in leukemiji mačk.
FeLV recombinant canarypox virus (vCP97) .................................................................. ≥ 107.2 CCID501 1 cell culture infective dose 50%.
(vCP97) ............................................................................................................................. ≥ 107,2 CCID501
Per dose of 1 ml: FHV (F2 strain) ................................................................................................................. ≥ 104.9 CCID50
V odmerku po 1 ml: FHV (sev F2) ..................................................................................................................... ≥ 104,9 CCID50
In normal conditions of use, transient apathy and anorexia may occasionally occur, as well as hyperthermia (lasting usually for 1 or 2 days).
Lahko se pojavi tudi povišana telesna temperatura (običajno traja 1 do 2 dni).
Onsets of immunity have been demonstrated 1 week after primary vaccination course for rhinotracheitis, calicivirus, Chlamydophila felis and panleucopenia components, and 2 weeks after primary vaccination course for feline leukaemia component.
Imunost proti kužnemu rinotraheitisu, okužbam s kalicivirusi, okužbam s Chlamydophila felis in panleukopeniji mačk nastopi 1 teden po osnovnem cepljenju.
Where high levels of maternal antibodies against rhinotracheitis, calicivirosis, panleucopenia or Chlamydophila components are expected to be present (e.g. in kittens of 9-12 weeks of age born from queens which were vaccinated before pregnancy and/or with known or suspected previous exposure to the pathogen(s)), the primary vaccination course should be delayed until 12 weeks of age.
panleukopenije ali Chlamydophile (na primer pri mladičih starih od 9 do 12 tednov, rojenih mačkam,
Disodium hydrogen orthophosphate Monopotassium phosphate anhydrous Potassium chloride
Natrijev hidrogenfosfat Kalijev dihidrogenfosfat, brezvodni Kalijev klorid
FeLV recombinant canarypox virus (vCP97)................................................................... ≥ 107.2 CCID50.
Atenuirani herpes virus rinotraheitisa mačk (sev FHV F2) ............................................. ≥ 104,9 CCID501
Attenuated feline rhinotracheitis herpesvirus (FHV F2 strain) ....................................... ≥ 104.9 CCID501 Inactivated feline calicivirus (FCV 431 and FCV G1 strains) antigens .......................... ≥ 2.0 ELISA U. Attenuated Chlamydophila felis (905 strain) ...................................................................... ≥ 103.0 EID502 Attenuated feline panleucopenia virus (PLI IV) ............................................................. ≥ 103.5 CCID501
Inaktivirani antigeni kalici virusa mačk (sev FCV 431 in G1) ......................... ≥ 2,0 enot v testu ELISA